Imagine using tiny, dissolvable beads to temporarily block blood flow to an inflamed knee joint, similar to how a temporary plug stops a leak. These beads stop the joint from breaking down and reduce pain, then simply melt away into the body after five days. This means no permanent foreign objects are left behind, keeping the knee clear for any future treatments.
Knee Osteoarthritis affects 30 million people in the EU/US, with 66% of patients eventually requiring invasive knee replacement due to the failure of existing drug therapies.
SakuraBead resorbable 200µm microspheres and a specialized microcatheter for targeted delivery to the knee.
If you are a distributor dealing with the high failure rate of KOA drugs — this project developed SakuraBead resorbable microspheres that provide long-term pain relief. It offers a drug-free alternative for the 30 million people currently treating KOA in the EU and US.
If you are a clinic dealing with the fact that two-thirds of KOA patients eventually need knee replacements — this project developed a minimally invasive catheter delivery system. It aims to stop disease progression for up to 5 years, delaying or preventing invasive surgery.
If you are a manufacturer dealing with the need for high-precision biocompatible particle production — this project developed a validated class 8 cleanroom process. This infrastructure allows for the production of tightly calibrated 200µm particles.
Based on available project data, specific pricing or cost per treatment is not provided.
The project has established and validated a state-of-the-art class 8 cleanroom within the CrannMed facility to support production.
The project utilizes patented bioresorbable particles developed by CrannMed.
The team is currently poised to embark on clinical evaluation and secure regulatory approvals following successful pre-clinical testing.
The particles are delivered via a specialized, minimally invasive microcatheter designed to reach the tortuous vessels of the knee.
The project is led by a single partner, CrannMed Ltd, an Irish SME. With a 100% industry ratio and no university or research partners, the project is driven by a commercial entity focused on rapid translation from engineering to clinical application.
Contact CrannMed Ltd in Ireland regarding SakuraBead clinical partnerships.
Contact us to explore licensing opportunities for resorbable embolic materials.
